Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Total Liabilities (2016 - 2025)

Voyager Therapeutics' Total Liabilities history spans 11 years, with the latest figure at $56.2 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 39.76% year-over-year to $56.2 million; the TTM value through Dec 2025 reached $56.2 million, down 39.76%, while the annual FY2025 figure was $56.2 million, 39.76% down from the prior year.
  • Total Liabilities for Q4 2025 was $56.2 million at Voyager Therapeutics, down from $68.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $148.3 million in Q1 2022 and bottomed at $56.2 million in Q4 2025.
  • The 5-year median for Total Liabilities is $100.6 million (2022), against an average of $102.3 million.
  • The largest annual shift saw Total Liabilities crashed 58.2% in 2021 before it surged 46.05% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $98.8 million in 2021, then grew by 1.55% to $100.3 million in 2022, then grew by 14.58% to $115.0 million in 2023, then dropped by 18.85% to $93.3 million in 2024, then tumbled by 39.76% to $56.2 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Total Liabilities are $56.2 million (Q4 2025), $68.5 million (Q3 2025), and $78.2 million (Q2 2025).